Literature DB >> 23387492

Evaluation of adenosine deaminase activity for the diagnosis of pleural TB in lymphocytic pleural effusions.

Cyro Teixeira da Silva1, Rodolfo Fred Behrsin, Gilberto Perez Cardoso, Elizabeth Giestal de Araújo.   

Abstract

AIM: To evaluate the diagnostic value of pleural adenosine deaminase (P-ADA) as a pleural TB-specific biomarker in lymphocytic pleural effusions. MATERIALS &
METHODS: Pleural effusions were classified on the basis of definitive diagnosis.
RESULTS: A total of 218 patients (122 tuberculous and 96 nontuberculous) were included in the study. The optimal cut-off value of P-ADA (receiver operating characteristic curve) for the diagnosis of pleural TB was 40.0 U/l (Giusti method). In lymphocytic pleural effusions P-ADA had a sensitivity of 80.3%, a specificity of 96.0% and an accuracy of 86.2%. The positive predictive value was 97.0% and the negative predictive value was 75.0%. The positive likelihood ratio and negative likelihood ratio were 19.8 and 0.2, respectively (p < 0.0001).
CONCLUSION: P-ADA activity is recommended for the diagnosis of TB in lymphocytic pleural effusions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23387492     DOI: 10.2217/bmm.12.89

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  2 in total

1.  Potential diagnostic value of serum/pleural fluid IL-31 levels for tuberculous pleural effusion.

Authors:  Yan Gao; Qinfang Ou; Jing Wu; Bingyan Zhang; Lei Shen; Shaolong Chen; Xinhua Weng; Ying Zhang; Wenhong Zhang; Lingyun Shao
Journal:  Sci Rep       Date:  2016-02-11       Impact factor: 4.379

2.  Diagnostic Accuracy with Total Adenosine Deaminase as a Biomarker for Discriminating Pleural Transudates and Exudates in a Population-Based Cohort Study.

Authors:  Bernardo Henrique Ferraz Maranhão; Cyro Teixeira da Silva Junior; Jorge Luiz Barillo; Carmem Lucia Teixeira de Castro; Joeber Bernardo Soares de Souza; Patricia Siqueira Silva; Roberto Stirbulov
Journal:  Dis Markers       Date:  2021-04-10       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.